<DOC>
	<DOCNO>NCT00006256</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining paclitaxel radiation therapy may kill tumor cell . PURPOSE : This trial study effectiveness concurrent administration chemotherapy radiation therapy treat woman stage II stage III breast cancer examine complication cosmetic effect .</brief_summary>
	<brief_title>Paclitaxel Plus Radiation Therapy Treating Women With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility concurrent paclitaxel breast radiotherapy woman stage II III breast cancer primary breast conserving surgery adjuvant chemotherapy . - Assess cosmetic result breast conservation treatment patient . - Determine pulmonary toxicity regimen patient . OUTLINE : Patients receive paclitaxel IV 3 hour every 21 day 4 course begin 3 week completion last doxorubicin cyclophosphamide adjuvant regimen . Patients also undergo concurrent radiotherapy 5 day week approximately 6-7 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow 1 month , every 3 month 1 year , every 6 month next 5 year , annually thereafter . PROJECTED ACCRUAL : Approximately 40 patient accrue study 12-18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage II III invasive breast cancer Prior breast conserving surgery ( lumpectomy quadrantectomy ) ipsilateral axillary lymph node dissection require No prior contralateral breast cancer No metastatic disease Prior ductal carcinoma situ lobular carcinoma situ breast allow unless treat radiation chemotherapy Doxorubicin cyclophosphamide adjuvant chemotherapy complete within past 3 week Candidate definitive radiotherapy Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT/AST great 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No concurrent poorly control ischemic heart disease congestive heart failure LVEF least 45 % MUGA scan echocardiogram Pulmonary : No concurrent severe chronic obstructive restrictive pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent severe medical psychiatric illness No concurrent severe diabetes mellitus No prior malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix treat local excision PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics Prior tamoxifen allow No concurrent tamoxifen Endocrine therapy : Not specify Radiotherapy : No prior radiation breast Surgery : Recovered form prior surgery Other : No concurrent adjuvant therapy another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>